EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT

Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial

Atezolizumab plus paclitaxel and bevacizumab as first-line treatment 1 of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial 

SUBSTUDY - CEBBRAH: Translational analysis of cerebrospinal fluid (CSF) and plasma circulating tumor DNA (ctDNA) from breast cancer patients (pts) with leptomeningeal disease (LMD) treated with trastuzumab deruxtecan (T-DXd) in the DEBBRAH trial

Patritumab deruxtecan (HER3-DXd) in active brain metastases (BM) from metastatic breast (mBC) and non–small cell lung cancers (aNSCLC), and leptomeningeal disease (LMD) from advanced solid tumors: results from the TUXEDO-3 phase II trial   

Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial  

Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: the PHENOMENAL phase 2 study

PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients

Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA Trial

A randomized phase II study to evaluate the effi cacy and safety of Trastuzumab deruxtecan (T-DXd) versus CDK4/6 inhibitor-basedendocrine therapy as fi rst-line therapy of hormone receptor-positive (HR+) and HER2-low/ultralow advanced breast cancer (ABC)patients classifi ed as non-luminal subtype according to gene expression profi ling: the PONTIAC study

Double-blind, Placebo-controlled, Randomized Phase 3 Trial of Elacestrant (ELA) + Everolimus (EVE) Versus ELA + Placebo (PBO) in ER+/HER2- Advanced Breast Cancer (aBC) Patients (pts) with ESR1-mutated Tumors Progressing on Endocrine Therapy (ET) + CDK4/6i

Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study

Lurbinectedin plus pembrolizumab in relapsed small cell lung cancer (SCLC): the phase I/II LUPER study